Search
for

    Sort by

    Research 691–720 of 1000+

    1. Proxalutamide (GT0918) Reduces the Rate of Hospitalization in mild-to-moderate COVID-19 Female Patients: A Randomized Double-Blinded Placebo-Controlled Two-Arm Parallel Trial medRxiv (Cold Spring Harbor Laboratory) · 2021 · 5 citations
    2. 5-Alpha-Reductase Inhibitors Reduce Remission Time of COVID-19: Results From a Randomized Double Blind Placebo Controlled Interventional Trial in 130 SARS-CoV-2 Positive Men medRxiv (Cold Spring Harbor Laboratory) · 2020 · 5 citations
    3. Post-acute COVID-19 syndrome and its prolonged effects: An updated systematic review medRxiv (Cold Spring Harbor Laboratory) · 2021 · 4 citations
    4. Differential risk for COVID-19 in the first wave of the disease (February-April 2020) among migrants from several areas of the world living in Alcorcón (Spain): A population-based cohort study bioRxiv (Cold Spring Harbor Laboratory) · 2020 · 4 citations
    5. Analyzing the laser-light reflection from human hair fibers. I. Light components underlying the goniophotometric curves and fiber cuticle angles. PubMed · 2003 · 3 citations
    6. Genomic Analysis of Trichotillomania medRxiv · 2025 · 1 citations
    7. Multi-omics empowered deep phenotyping of ulcerative colitis bioRxiv (Cold Spring Harbor Laboratory) · 2022 · 1 citations
    8. The Use/Abuse of Oral Contraceptive Pills Among Males: A Mixed-Method Explanatory Sequential Study Over Jordanian Community Pharmacists medRxiv (Cold Spring Harbor Laboratory) · 2021 · 1 citations
    9. Multi-Herbal Extracellular Vesicle and Growth Factor Serum for Eyelash Care: A Pilot Randomized, Double Blind, Placebo-Controlled Clinical Study medRxiv · 2026
    10. ONCO-NK-TRANSITION-GM1: The Bridge Cancer Therapy Manufacturable by Current Pharmaceutical Industry — 60-80% Cure Rate — $50 per Dose A Complete Transitional Drug from Full N‑K GM Series to Current Pharma Capability Zenodo (CERN European Organization for Nuclear Research) · 2026
    11. ONCO-NK-TRANSITION-GM1: The Bridge Cancer Therapy Manufacturable by Current Pharmaceutical Industry — 60-80% Cure Rate — $50 per Dose A Complete Transitional Drug from Full N‑K GM Series to Current Pharma Capability Zenodo (CERN European Organization for Nuclear Research) · 2026
    12. Advancing Hair Loss Assessment in Alopecia Areata: The Mathematical Case for Centralised, Standardised Imaging medRxiv · 2026
    13. Health-related quality of life in mild-moderate patchy alopecia areata: Results from the first controlled Phase 2 clinical trial in this population with STS01 (dithranol/ProSilic) and challenges for the future medRxiv · 2026
    14. Recyclable Polymerizable Deep Eutectic Solvent-Based Three-Dimensional-Printed Dissolving Microneedles with pH-Responsive Delivery of ZIF-8-Loaded Minoxidil for Hair Loss Therapy ACS Applied Materials & Interfaces · 2026
    15. A 56-Day Randomized, Double-Blinded, and Placebo-Controlled Clinical Assessment of Scalp Health and Hair Growth Parameters with a Centella asiatica Extracellular Vesicle and Growth Factor-Based Essence medRxiv (Cold Spring Harbor Laboratory) · 2025
    16. The polygenic architecture of hidradenitis suppurativa reveals signaling mechanisms that implicate epithelial remodeling 2025
    17. Causal Relationship Between Gut Microbiota and Androgenic Alopecia: A Mendelian Randomization Analysis 2025
    18. Demonstrating the potential of untargeted hair proteomics for personalized biomarkers in stress-associated disorders medRxiv (Cold Spring Harbor Laboratory) · 2025
    19. Risk of Alopecia Areata with Glucagon-Like Peptide-1 Receptor Agonists for Weight Loss medRxiv (Cold Spring Harbor Laboratory) · 2025
    20. The genetic basis of dermatophytosis skin infection susceptibility medRxiv (Cold Spring Harbor Laboratory) · 2024
    21. Chronic Overlapping Pain Conditions and Nociplastic Pain medRxiv (Cold Spring Harbor Laboratory) · 2023
    22. Paroxysmal Nocturnal Hemoglobinuria in Systemic Lupus Erythematosus: A Rare Manifestation. PubMed · 2023
    23. Medication Clusters at Hospital Discharge and Risk of Adverse Drug Events at 30-days Post-Discharge: A Population-based Cohort Study of Older Adults medRxiv (Cold Spring Harbor Laboratory) · 2022
    24. A qualitative phase I study protocol on developing patient-reported outcome measure for hair, scalp, eyebrows, eyelashes, and beard-related skin disorders medRxiv (Cold Spring Harbor Laboratory) · 2022
    25. Peer Review #1 of "Melatonin increases growth properties in human dermal papilla spheroids by activating AKT/GSK3β/β-Catenin signaling pathway (v0.1)" 2022
    26. Peer Review #2 of "Melatonin increases growth properties in human dermal papilla spheroids by activating AKT/GSK3β/β-Catenin signaling pathway (v0.1)" 2022
    27. Peer Review #2 of "Melatonin increases growth properties in human dermal papilla spheroids by activating AKT/GSK3β/β-Catenin signaling pathway (v0.2)" 2022
    28. Blood group O and post-COVID-19 syndrome medRxiv (Cold Spring Harbor Laboratory) · 2022
    29. Multimodal Recruitment for an Internet-Based Pilot Study of Ovulation and Menstruation (OM) Health 2020
    30. Review of Different DNA Extraction Methods in Hair Shafts Zhongguo shengwu gongcheng zazhi · 2012